HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.

AbstractAIM:
We aimed to clarify which breast cancer subtypes respond best to docetaxel/cyclophosphamide chemotherapy (TC) as neoadjuvant chemotherapy (NAC).
PATIENTS AND METHODS:
We analyzed pathological responses, clinicopathological characteristics and biological markers (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, p53, topoisomerase IIα, class III β tubulin, cytokeratin 5/6, epidermal growth factor receptor (EGFR)) in specimens from 79 patients who received NAC-TC.
RESULTS:
Out of 79 patients, 33 (41.8%) achieved quasipathological complete responses (QpCR). Univariate analysis associated negative ER (p<0.001), negative PR (p=0.007), triple-negative subtype (TNBC; p=0.001), high Ki-67 (p=0.022) and low class III β tubulin (p=0.032) with QpCR. Multivariate analyses associated only negative ER (p=0.050) and low class III β tubulin (p=0.028) and only non-basal subtype in TNBC with QpCR.
CONCLUSION:
NAC-TC may be especially effective in ER-breast cancer with low class III β tubulin or non-basal TNBC.
AuthorsKazuhiro Shimada, Takashi Ishikawa, Kumiko Kita, Kazutaka Narui, Sadayoshi Sugae, Daisuke Shimizu, Mikiko Tanabe, Takeshi Sasaki, Takashi Chishima, Yasushi Ichikawa, Itaru Endo
JournalAnticancer research (Anticancer Res) Vol. 35 Issue 2 Pg. 907-12 (Feb 2015) ISSN: 1791-7530 [Electronic] Greece
PMID25667473 (Publication Type: Journal Article)
CopyrightCopyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Taxoids
  • Tubulin
  • Docetaxel
  • Cyclophosphamide
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (metabolism)
  • Chemotherapy, Adjuvant
  • Cyclophosphamide (administration & dosage)
  • Docetaxel
  • Female
  • Humans
  • Middle Aged
  • Taxoids (administration & dosage)
  • Triple Negative Breast Neoplasms (drug therapy, metabolism)
  • Tubulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: